Terasawa Risa, Takashima Yuko, Hirata Aiko, Kimura Kosei, Morita Shinsho, Hayash Michihiro
Dept. of Breast and Endocrine Surgery, Hirakata City Hospital.
Gan To Kagaku Ryoho. 2023 May;50(5):635-637.
Drug-induced interstitial lung disease(DILD)is a possible complication of many anticancer drugs. When DILD occurs during breast cancer treatment, choosing the right drug for subsequent treatment is often difficult. In our first case, the patient developed DILD during dose-dense AC(ddAC)therapy; however, the disease resolved with steroid pulse therapy, and the patient underwent surgery without disease progression. In the second case, a patient on anti-HER2 therapy for recurrent disease developed DILD in response to docetaxel plus trastuzumab plus pertuzumab administered to treat T-DM1 after progressive disease. In this report, we describe a case of DILD that did not worsen and the patient had successful treatment outcome.
药物性间质性肺病（DILD）是许多抗癌药物可能引发的并发症。当乳腺癌治疗期间发生DILD时，为后续治疗选择合适的药物往往很困难。在我们的第一个病例中，患者在密集剂量AC（ddAC）治疗期间发生了DILD；然而，通过类固醇脉冲疗法疾病得到缓解，并且患者在无疾病进展的情况下接受了手术。在第二个病例中，一名复发性疾病接受抗HER2治疗的患者，在疾病进展后接受多西他赛加曲妥珠单抗加帕妥珠单抗治疗T-DM1时发生了DILD。在本报告中，我们描述了一例DILD未恶化且患者治疗结果成功的病例。
